Cite
Supplementary Figure 1 from Ganitumab (AMG 479) Inhibits IGF-II–Dependent Ovarian Cancer Growth and Potentiates Platinum-Based Chemotherapy
MLA
Gottfried E. Konecny, et al. Supplementary Figure 1 from Ganitumab (AMG 479) Inhibits IGF-II–Dependent Ovarian Cancer Growth and Potentiates Platinum-Based Chemotherapy. Mar. 2023. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....2dc538cb1a92ebb99af5688bbe8bdb33&authtype=sso&custid=ns315887.
APA
Gottfried E. Konecny, Dennis J. Slamon, Jingwei Qi, Guorong Yang, Victor E. Velculescu, Steven Vonderfecht, Chi-Ming Li, Brian Belmontes, Gordon Moody, Elaina Cajulis, Young-Ah Chung, Petia Mitchell, Frank J. Calzone, & Pedro J. Beltran. (2023). Supplementary Figure 1 from Ganitumab (AMG 479) Inhibits IGF-II–Dependent Ovarian Cancer Growth and Potentiates Platinum-Based Chemotherapy.
Chicago
Gottfried E. Konecny, Dennis J. Slamon, Jingwei Qi, Guorong Yang, Victor E. Velculescu, Steven Vonderfecht, Chi-Ming Li, et al. 2023. “Supplementary Figure 1 from Ganitumab (AMG 479) Inhibits IGF-II–Dependent Ovarian Cancer Growth and Potentiates Platinum-Based Chemotherapy,” March. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....2dc538cb1a92ebb99af5688bbe8bdb33&authtype=sso&custid=ns315887.